Advertisement

Neoadjuvant Chemotherapy of Gastric Cancer with UFT

  • Yoshinori Nio
  • Chikage Iguchi
  • Kunihiro Yamasawa
  • Masayuki Itakura
  • Hiroshi Omori
  • Koji Hashimoto
  • Seiji Yano
  • Shoichiro Sumi
  • Katsuhiro Tamura

Abstract

Gastric cancer is the most common cancer in Japan. The treatment results for gastric cancer in Japan have been improving over the last two decades, and the 5-year survival rates after surgery have reached more than 90% for stage 1 and 70%–80% for stage 2. The prognosis of patients with stage 3 or 4 gastric cancer is still poor, and 5-year survival rates are about 40% for stage 3 and 5%–10% for stage 4. To improve the treatment results for gastric cancer, a variety of therapies have been applied, with chemotherapy playing the most important role. It is still unclear whether postoperative adjuvant chemotherapy improves survival, although gastric cancer is now considered to be relatively sensitive to chemotherapy compared to that of other digestive organ cancers.

Keywords

Gastric Cancer Clin Oncol Objective Response Advanced Gastric Cancer Preoperative Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wagener DJT, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ, Scheerder H, van der Vegt SGL (1985) Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15:86–87PubMedCrossRefGoogle Scholar
  2. 2.
    Moertel CG, Rubin J, O’Connel MJ, Schutt AJ, Wieand HS (1986) A phase II trial of 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053–1057PubMedGoogle Scholar
  3. 3.
    Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317PubMedGoogle Scholar
  4. 4.
    Sparano JA, Schwartz EL, Salva KM, Pizzilo MF, Wadler S, Wiernik PH (1990) Phase II trial of etoposide, doxorubicin (adriamycin) and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13:374–378PubMedCrossRefGoogle Scholar
  5. 5.
    Stephens FO, Adams BG, Crea P (1986) Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 162:370–374PubMedGoogle Scholar
  6. 6.
    Wilke H, Preusser U, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, Schmoll HJ (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318–1326PubMedGoogle Scholar
  7. 7.
    Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohyama S, Takashima T, Kimura H, Kamata T (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17:256–262PubMedCrossRefGoogle Scholar
  8. 8.
    Arima S, Ohsato K, Hisatsugu T, Shimura H (1994) Multicenter randomized study of adjuvant chemotherapy with mitomycin-C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 160:227–232PubMedGoogle Scholar
  9. 9.
    Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan) (1995) A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer. Eur J Surg Oncol 21:69–77CrossRefGoogle Scholar
  10. 10.
    Ikeda K, Saitoh S, Koide I, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H (1995) A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18:204–210PubMedCrossRefGoogle Scholar
  11. 11.
    Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333–338PubMedCrossRefGoogle Scholar
  12. 12.
    Nio Y, Tseng CC, Shiraishi T, Tsubono M, Kawabata K, Masai Y, Hayashi H, Fukumoto M, Nio M, Sato M, Mizuta J, Tobe T (1993) A phase II study of 5-fluorouracil, cisplatin and 4″-epirubicin (FPEPIR) in the treatment of advanced solid cancers. Am J Clin Oncol 16:96–101PubMedCrossRefGoogle Scholar
  13. 13.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  14. 14.
    Marunaka T, Umeno Y, Yoshida K, Nagamachi M, Minami Y, Fujii S (1980) High pressure liquid chromatographic determination of ftrafur [1-(tetrahydro-2-furanyl)-5-fluorouracil and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftrafur. J Pharmacokinet Sci 69:1296–1300CrossRefGoogle Scholar
  15. 16.
    Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B (1994) Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296–2300PubMedGoogle Scholar
  16. 17.
    Saltz LB, Leichman C, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP (1995) A fixed-ration combination of uracil and ftrafur (UFT) with low dose leucovorin. Cancer 75:782–785PubMedCrossRefGoogle Scholar
  17. 18.
    Nio Y, Tsubono M, Kawabata K, Masai Y, Hayashi H, Meyer C, Inoue K, Tobe T (1993) Comparison of survival curves of gastric cancer patients after surgery according to the UICC stage classification and the general rules for gastric cancer study by the Japanese Research Society for Gastric Cancer. Ann Surg 218:47–53PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Yoshinori Nio
    • 1
  • Chikage Iguchi
    • 1
  • Kunihiro Yamasawa
    • 1
  • Masayuki Itakura
    • 1
  • Hiroshi Omori
    • 1
  • Koji Hashimoto
    • 1
  • Seiji Yano
    • 1
  • Shoichiro Sumi
    • 1
  • Katsuhiro Tamura
    • 1
  1. 1.First Department of SurgeryShimane Medical UniversityShimaneJapan

Personalised recommendations